PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end
Palisade Bio Announces Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Covering PALI-2108, An Orally Administered PDE4 Inhibitor Prodrug For Ulcerative Colitis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated